OBJECTIVE: Knowing the timing of specific depressive symptom improvement will enable clinicians to prepare their patients well and improve treatment outcome, whereas recognizing which depressive symptoms may show delayed improvement will help clinicians to provide additional interventions early in treatment. In a prospective open-label fluoxetine study, we investigated the timing of depressive symptom improvement during acute treatment, and identified common remaining symptoms following 4, 8, and 12 weeks of acute treatment in depressed youths. METHOD: A total of 168 children and adolescents, aged 7-18 years, with primary diagnoses of major depressive disorder (MDD) received 12 weeks offluoxetine treatment. Youths were evaluated using the Kiddie Schedule for Affective Disorders and Schizophrenia. The outcome measure included the Children's Depression Rating Scale-Revised. RESULTS:All depressive symptoms improved, particularly during the first 4 weeks of acute treatment. Forty-seven percent of remitters reported at least one residual symptom following 12 weeks, with most common residual symptoms being impaired school performance, insomnia, and irritability. CONCLUSIONS: Residual symptoms are common, even among remitters, at the end of 12 weeks of acute treatment. There is a need for clinicians to monitor symptom improvement and potentially provide additional interventions for the more resistant symptoms, such as insomnia and school performance.
RCT Entities:
OBJECTIVE: Knowing the timing of specific depressive symptom improvement will enable clinicians to prepare their patients well and improve treatment outcome, whereas recognizing which depressive symptoms may show delayed improvement will help clinicians to provide additional interventions early in treatment. In a prospective open-label fluoxetine study, we investigated the timing of depressive symptom improvement during acute treatment, and identified common remaining symptoms following 4, 8, and 12 weeks of acute treatment in depressed youths. METHOD: A total of 168 children and adolescents, aged 7-18 years, with primary diagnoses of major depressive disorder (MDD) received 12 weeks of fluoxetine treatment. Youths were evaluated using the Kiddie Schedule for Affective Disorders and Schizophrenia. The outcome measure included the Children's Depression Rating Scale-Revised. RESULTS: All depressive symptoms improved, particularly during the first 4 weeks of acute treatment. Forty-seven percent of remitters reported at least one residual symptom following 12 weeks, with most common residual symptoms being impaired school performance, insomnia, and irritability. CONCLUSIONS: Residual symptoms are common, even among remitters, at the end of 12 weeks of acute treatment. There is a need for clinicians to monitor symptom improvement and potentially provide additional interventions for the more resistant symptoms, such as insomnia and school performance.
Authors: Craig H Mallinckrodt; Todd M Sanger; Sanjay Dubé; David J DeBrota; Geert Molenberghs; Raymond J Carroll; William Z Potter; Gary D Tollefson Journal: Biol Psychiatry Date: 2003-04-15 Impact factor: 13.382
Authors: J Kaufman; B Birmaher; D Brent; U Rao; C Flynn; P Moreci; D Williamson; N Ryan Journal: J Am Acad Child Adolesc Psychiatry Date: 1997-07 Impact factor: 8.829
Authors: A John Rush; Helena C Kraemer; Harold A Sackeim; Maurizio Fava; Madhukar H Trivedi; Ellen Frank; Philip T Ninan; Michael E Thase; Alan J Gelenberg; David J Kupfer; Darrel A Regier; Jerrold F Rosenbaum; Oakley Ray; Alan F Schatzberg Journal: Neuropsychopharmacology Date: 2006-06-21 Impact factor: 7.853
Authors: Ying Guo; Mary E Nilsson; John Heiligenstein; Michael G Wilson; Graham Emslie Journal: J Child Adolesc Psychopharmacol Date: 2006-08 Impact factor: 2.576
Authors: Betsy Kennard; Susan Silva; Benedetto Vitiello; John Curry; Christopher Kratochvil; Anne Simons; Jennifer Hughes; Norah Feeny; Elizabeth Weller; Michael Sweeney; Mark Reinecke; Sanjeev Pathak; Golda Ginsburg; Graham Emslie; John March Journal: J Am Acad Child Adolesc Psychiatry Date: 2006-12 Impact factor: 8.829
Authors: John March; Susan Silva; Stephen Petrycki; John Curry; Karen Wells; John Fairbank; Barbara Burns; Marisa Domino; Steven McNulty; Benedetto Vitiello; Joanne Severe Journal: JAMA Date: 2004-08-18 Impact factor: 56.272
Authors: Graham J Emslie; John H Heiligenstein; Karen Dineen Wagner; Sharon L Hoog; Daniel E Ernest; Eileen Brown; Mary Nilsson; Jennie G Jacobson Journal: J Am Acad Child Adolesc Psychiatry Date: 2002-10 Impact factor: 8.829
Authors: Lara C Foland-Ross; Matthew D Sacchet; Gautam Prasad; Brooke Gilbert; Paul M Thompson; Ian H Gotlib Journal: Int J Dev Neurosci Date: 2015-08-24 Impact factor: 2.457
Authors: Dana L McMakin; Thomas M Olino; Giovanna Porta; Laura J Dietz; Graham Emslie; Gregory Clarke; Karen Dineen Wagner; Joan R Asarnow; Neal D Ryan; Boris Birmaher; Wael Shamseddeen; Taryn Mayes; Betsy Kennard; Anthony Spirito; Martin Keller; Frances L Lynch; John F Dickerson; David A Brent Journal: J Am Acad Child Adolesc Psychiatry Date: 2012-03-03 Impact factor: 8.829
Authors: Glenda M MacQueen; Benicio N Frey; Zahinoor Ismail; Natalia Jaworska; Meir Steiner; Ryan J Van Lieshout; Sidney H Kennedy; Raymond W Lam; Roumen V Milev; Sagar V Parikh; Arun V Ravindran Journal: Can J Psychiatry Date: 2016-08-02 Impact factor: 4.356
Authors: Graham J Emslie; Betsy D Kennard; Taryn L Mayes; Paul A Nakonezny; Lian Zhu; Rongrong Tao; Carroll Hughes; Paul Croarkin Journal: J Child Adolesc Psychopharmacol Date: 2012-01-18 Impact factor: 2.576